GGrantIndex
← Search

CORE--CLINICAL TRIAL PROTOCOL REVIEW AND MONITORING SYSTEM

$167,178P30FY2002CANIH

University Of California Los Angeles, Los Angeles CA

Investigators

Linked publications, trials & patents

Trial NCT07339085Trial NCT07276438Trial NCT07242365Trial NCT06650163Trial NCT06568016Trial NCT06113016Trial NCT05595499Trial NCT04205838Trial NCT04201873Trial NCT04185311Trial NCT04119024Trial NCT04106362Trial NCT04069923Trial NCT04069910Trial NCT04050215Trial NCT04007029Trial NCT03996850Trial NCT03970252Trial NCT03953157Trial NCT03904251Trial NCT03902951Trial NCT03892720Trial NCT03830918Trial NCT03825796Trial NCT03745690Trial NCT03732950Trial NCT03732352Trial NCT03672773Trial NCT03623854Trial NCT03618134Trial NCT03603223Trial NCT03601455Trial NCT03596710Trial NCT03582774Trial NCT03582475Trial NCT03541850Trial NCT03515577Trial NCT03506802Trial NCT03425461Trial NCT03411070Trial NCT03368547Trial NCT03319342Trial NCT03240861Trial NCT03202472Trial NCT03128619Trial NCT03025139Trial NCT03014804Trial NCT02940262Trial NCT02928510Trial NCT02925351Trial NCT02919332Trial NCT02902757Trial NCT02888301Trial NCT02881242Trial NCT02880020Trial NCT02879994Trial NCT02830165Trial NCT02816879Trial NCT02775292Trial NCT02756130Trial NCT02701153Trial NCT02688348Trial NCT02683200Trial NCT02672033Trial NCT02597894Trial NCT02575027Trial NCT02451865Trial NCT02336763Trial NCT02310594Trial NCT02296229Trial NCT02280161Trial NCT02263898Trial NCT02176902Trial NCT02070406Trial NCT02049593Trial NCT02048020Trial NCT02015559Trial NCT01912820Trial NCT01013285Trial NCT01005472Trial NCT00999557Trial NCT00998010Trial NCT00985192Trial NCT00955591Trial NCT00882765Trial NCT00880542Trial NCT00769470Trial NCT00706615Trial NCT00685516Trial NCT00616642Trial NCT00612066Trial NCT00601289Trial NCT00601094Trial NCT00521209Trial NCT00509431Trial NCT00471887Trial NCT00450567Trial NCT00444223Trial NCT00352001Trial NCT00349167

Abstract

Description: The Internal Scientific Protocol Review Committee, chaired by Dr. John A. Glaspy, was approved conditionally for early peer reevaluation during the last review. Two peer review evaluations occurred during the interim at the Parent Committee level. The first resulted in disapproval; the second awarded approval for the ISPRC process. The key elements at that time were a memo from the Chancellor indicating that all cancer-related research done at UCLA needed to have approval of the ISPRC for scientific merit prior to its submission to the IRB and evidence of more rigorous committee function. In addition, expanded committee membership, including a broader range of oncology disciplines and oncology research, had been instituted. A statistical checkoff had also been established to assure that all protocols have been seen by Cancer Center biostatisticians prior to their submission. The present application provides evidence that all protocols are being reapproved annually after re-review prior to the IRB submission. The committee now consists of 11 members representing biostatistics, cancer control, pharmacy, research nursing, and a spectrum of oncologists. For new protocol submissions, the committee uses a standard set of criteria. Most disapprovals over the past year are based upon one of the following: 1) insufficient scientific merit; 2) inadequate biostatistical analytical sections; 3) overlap with existing protocols without an obvious need for the secondary protocol; and 4) inability to support and carry out the protocol due to lack of adequate resources. With respect to the annual renewal, most disapprovals of those continuations were based upon one of the following: the rate of accrual is substantially lower than the originally stated target; the total accrual has met the originally stated target; or a report of the Quality Control Committee of any of the investigator's studies indicating that the research has not been conducted in a fashion that will lead to generation of correct and valid conclusions.

View original record on NIH RePORTER →